Home › Seattle Genetics and Takeda Announce Four-Year Survival Data from...
 

Keywords :   


Seattle Genetics and Takeda Announce Four-Year Survival Data from...

2014-12-08 13:13:49| Biotech - Topix.net

Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited has announced four-year overall survival data from the ADCETRIS pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma . ADCETRIS is an antibody-drug conjugate directed to CD30, which is expressed in classical Hodgkin lymphoma and systemic ALCL, a type of T-cell lymphoma.

Tags: from data seattle survival

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05WCC Re-elects Tom Bowtell for Second Term as President, Recognizes Contributions of Andy Doyle
20.05May/June 2024 Digital Edition of National Hog Farmer now available
20.05DKSH Extends Distribution Agreement with KRONOS in Asia Pacific
20.05NABC hosts foreign animal disease tabletop exercise
20.05NABC hosts foreign animal disease tabletop exercise
20.05Printed Easy increases capacity by 300% with Durst
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
More »